A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : CK / compound K

[Related PubMed/MEDLINE]
Total Number of Papers: 110
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   CK  (>> Co-occurring Abbreviation)
Long Form:   compound K
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Compound K, a ginsenoside metabolite, plays an antiinflammatory role in macrophages by targeting the AKT1-mediated signaling pathway. LPS
2019 Development of Lactobacillus kimchicus DCY51T-mediated gold nanoparticles for delivery of ginsenoside compound K: in vitro photothermal effects and apoptosis detection in cancer cells. DLS, EDX, FE-TEM, FTIR, LC-MS, SAED, XRD
2019 Ginsenoside compound K attenuates cognitive deficits in vascular dementia rats by reducing the Abeta deposition. Abeta1-42, CCH, IDE, PI3K, pSer9-GSK3beta, VD
2019 Ginsenoside compound K protects human umbilical vein endothelial cells against oxidized low-density lipoprotein-induced injury via inhibition of nuclear factor-kappaB, p38, and JNK MAPK pathways. HUVECs, JNK, MAPK, NF, oxLDL, PI
2019 Ginsenoside Compound K Regulates Amyloid beta via the Nrf2/Keap1 Signaling Pathway in Mice with Scopolamine Hydrobromide-Induced Memory Impairments. ---
2019 LC-MS/MS determination of ginsenoside compound K and its metabolite 20(S)-protopanaxadiol in human plasma and urine: applications in a clinical study. ---
2019 Pharmacokinetic Study of Compound K in Japanese Subjects After Ingestion of Panax ginseng Fermented by Lactobacillus paracasei A221 Reveals Significant Increase of Absorption into Blood. AUC, FG, NFG
2019 Production of Triterpene Ginsenoside Compound K in the Non-conventional Yeast Yarrowia lipolytica. ---
2019 Study of the Effects and Mechanisms of Ginsenoside Compound K on Myelosuppression. BMNCs
10  2019 Synthesis and biological evaluation of Ginsenoside Compound K analogues as a novel class of anti-asthmatic agents. ---
11  2018 An L213A variant of beta-glycosidase from Sulfolobus solfataricus with increased alpha-L-arabinofuranosidase activity converts ginsenoside Rc to compound K. C-Mc, PPD
12  2018 Antidepressant Effects of the Ginsenoside Metabolite Compound K, Assessed by Behavioral Despair Test and Chronic Unpredictable Mild Stress Model. 5-HT, CNS, CUMS, DA, FST, PFC, TST
13  2018 Compound K attenuates glucose intolerance and hepatic steatosis through AMPK-dependent pathways in type 2 diabetic OLETF rats. AMPK, HFD, OLETF
14  2018 Compound K Inhibits Autophagy-Mediated Apoptosis Through Activation of the PI3K-Akt Signaling Pathway Thus Protecting Against Ischemia/Reperfusion Injury. I/R, ROS
15  2018 Enhanced cytotoxic and apoptotic potential in hepatic carcinoma cells of chitosan nanoparticles loaded with ginsenoside compound K. ---
16  2018 Fecal metabolomic dataset of American ginseng-treated DSS mice: Correlation between ginseng enteric inflammation inhibition and its biological signatures. ---
17  2018 Ginseng polysaccharides enhanced ginsenoside Rb1 and microbial metabolites exposure through enhancing intestinal absorption and affecting gut microbial metabolism. DSS, GP, GP, PPD, TCMs
18  2018 Ginsenoside metabolite compound K exerts anti-inflammatory and analgesic effects via downregulating COX2. COX-1, ELISA, PGE2
19  2018 Highly Selective Production of Compound K from Ginsenoside Rd by Hydrolyzing Glucose at C-3 Glycoside Using beta-glucosidase of Bifidobacterium breve ATCC 15700. ---
20  2018 Preparation of ginsenoside compound-K mixed micelles with improved retention and antitumor efficacy. PC
21  2018 Production of bioactive ginsenoside Rg3(S) and compound K using recombinant Lactococcus lactis. L.lactis NZ9000
22  2018 Protective effect of ginsenoside metabolite compound K against diabetic nephropathy by inhibiting NLRP3 inflammasome activation and NF-kappaB/p38 signaling pathway in high-fat diet/streptozotocin-induced diabetic mice. DN, HFD
23  2018 The combined administration of parthenolide and ginsenoside CK in long circulation liposomes with targeted tLyp-1 ligand induce mitochondria-mediated lung cancer apoptosis. ---
24  2018 The skin protective effects of compound K, a metabolite of ginsenoside Rb1 from Panax ginseng. ---
25  2017 Ascorbyl palmitate/d-alpha-tocopheryl polyethylene glycol 1000 succinate monoester mixed micelles for prolonged circulation and targeted delivery of compound K for antilung cancer therapy in vitro and in vivo. AP
26  2017 Enhanced antidiabetic efficacy and safety of compound K⁄beta-cyclodextrin inclusion complex in zebrafish. ATP, CD, TUNEL
27  2017 Food and Sex-Related Impacts on the Pharmacokinetics of a Single-Dose of Ginsenoside Compound K in Healthy Subjects. PPD
28  2017 Ginseng fermented by mycotoxin non-producing Aspergillus niger: ginsenoside analysis and anti-proliferative effects. A. niger
29  2017 Heterologous production of a ginsenoside saponin (compound K) and its precursors in transgenic tobacco impairs the vegetative and reproductive growth. DD
30  2017 Nuclear factor kappa-B- and activator protein-1-mediated immunostimulatory activity of compound K in monocytes and macrophages. CD
31  2017 Single- and Multiple-Dose Trials to Determine the Pharmacokinetics, Safety, Tolerability, and Sex Effect of Oral Ginsenoside Compound K in Healthy Chinese Volunteers. AEs, PPD, Tmax
32  2017 Targeted delivery of ginsenoside compound K using TPGS/PEG-PCL mixed micelles for effective treatment of lung cancer. ---
33  2017 The ginsenoside metabolite compound K inhibits growth, migration and stemness of glioblastoma cells. GBM, GSCs, mTOR, PARP, PI3K
34  2016 Antidepressant-like effects of ginsenosides: A comparison of ginsenoside Rb3 and its four deglycosylated derivatives, Rg3, Rh2, compound K, and 20(S)-protopanaxadiol in mice models of despair. ACTH, ELISA, FST, PPD, TST
35  2016 Compound K attenuates stromal cell-derived growth factor 1 (SDF-1)-induced migration of C6 glioma cells. ERK, MMP, PKC, SDF-1
36  2016 Daikenchuto (TU-100) shapes gut microbiota architecture and increases the production of ginsenoside metabolite compound K. ---
37  2016 Effects of ginsenoside compound K combined with cisplatin on the proliferation, apoptosis and epithelial mesenchymal transition in MCF-7 cells of human breast cancer. Akt, CON, ELISA, EMT, FN, MTT, p-Akt
38  2016 Ginsenoside 20(S)-Protopanaxadiol Suppresses Viability of Human Glioblastoma Cells via Down-regulation of Cell Adhesion Proteins and Cell-cycle Arrest. GBM, PPD
39  2016 Ginsenoside compound K sensitizes human colon cancer cells to TRAIL-induced apoptosis via autophagy-dependent and -independent DR5 upregulation. CHOP, TNF
40  2016 Ginsenoside metabolite compound K exerts joint-protective effect by interfering with synoviocyte function mediated by TNF-alpha and Tumor necrosis factor receptor type 2. AA, FLS, GR, RA, TNFR1, TNFR2
41  2016 Ginsenoside Rb1 and compound K improve insulin signaling and inhibit ER stress-associated NLRP3 inflammasome activation in adipose tissue. ER
42  2016 Screening of Drug Metabolizing Enzymes for the Ginsenoside Compound K In Vitro: An Efficient Anti-Cancer Substance Originating from Panax Ginseng. HLMs
43  2015 A Bacterial Metabolite, Compound K, Induces Programmed Necrosis in MCF-7 Cells via GSK3beta. GSK3beta
44  2015 A gut microbial metabolite of ginsenosides, compound K, induces intestinal glucose absorption and Na(+) /glucose cotransporter 1 gene expression through activation of cAMP response element binding protein. CBP, CRE, CREB, EGFR, IECs
45  2015 A prebiotic fiber increases the formation and subsequent absorption of compound K following oral administration of ginseng in rats. ---
46  2015 Based on SERS conformational studies of ginsenoside Rb1 and its metabolites before and after combined with human serum albumin. HSA, SERS
47  2015 Compound K Production from Red Ginseng Extract by beta-Glycosidase from Sulfolobus solfataricus Supplemented with alpha-L-Arabinofuranosidase from Caldicellulosiruptor saccharolyticus. PPD, RGE
48  2015 Ginsenoside Compound K suppresses the hepatic gluconeogenesis via activating adenosine-5'monophosphate kinase: A study in vitro and in vivo. AMPK, G6Pase, HNF-4alpha, PEPCK, PGC-1alpha
49  2015 Ginsenoside metabolite compound K enhances the efficacy of cisplatin in lung cancer cells. CI
50  2015 Ginsenoside metabolite compound K suppresses T-cell priming via modulation of dendritic cell trafficking and costimulatory signals, resulting in alleviation of collagen-induced arthritis. CIA, DCs
51  2015 Ginsenosides Regulate PXR/NF-kappaB Signaling and Attenuate Dextran Sulfate Sodium-Induced Colitis. NF-kappaB, PXR
52  2015 Highly Selective Bioconversion of Ginsenoside Rb1 to Compound K by the Mycelium of Cordyceps sinensis under Optimized Conditions. HPLC-Q-TOF-MS
53  2015 Involvement of Wnt/beta-catenin signaling in the mesenchymal stem cells promote metastatic growth and chemoresistance of cholangiocarcinoma. hUCMSCs, MSC-CM, MSCs
54  2015 Niabella ginsenosidivorans sp. nov., isolated from compost. ---
55  2015 Protective effect of compound K on diabetic rats. BUN, FBG, GSH-Px, MDA, SCr, SOD, STZ, TC, TG, UA
56  2015 Selected ginsenosides of the protopanaxdiol series are novel positive allosteric modulators of P2X7 receptors. ---
57  2015 [Compound K suppresses myeloid-derived suppressor cells in a mouse model bearing CT26 colorectal cancer xenograft]. MDSCs
58  2014 Compound K inhibits MMP-1 expression through suppression of c-Src-dependent ERK activation in TNF-alpha-stimulated dermal fibroblast. EGFR, ERK, JNK, MMP-1, TNF-alpha
59  2014 Compound K protects pancreatic islet cells against apoptosis through inhibition of the AMPK/JNK pathway in type 2 diabetic mice and in MIN6 beta-cells. AMPK, JNK, T2D
60  2014 Effects of compound K on hyperglycemia and insulin resistance in rats with type 2 diabetes mellitus. BW, FBG, FINS, HFD, ISI, OGTT, STZ, T2DM, TC, TG
61  2014 Ginsenoside compound K induces apoptosis in nasopharyngeal carcinoma cells via activation of apoptosis-inducing factor. AIF, NPC, PD, PPD
62  2014 Ginsenoside compound K inhibits angiogenesis via regulation of sphingosine kinase-1 in human umbilical vein endothelial cells. HUVEC, S1P, SphK1
63  2014 Ginsenoside compound K suppresses the abnormal activation of T lymphocytes in mice with collagen-induced arthritis. CIA, CTLA-4, PD-1, TCR
64  2014 Ginsenoside compound K-bearing glycol chitosan conjugates: synthesis, physicochemical characterization, and in vitro biological studies. GC
65  2014 Ginsenoside metabolite compound k alleviates adjuvant-induced arthritis by suppressing T cell activation. AA, RA
66  2014 Ginsenoside metabolite compound K attenuates inflammatory responses of adjuvant-induced arthritis rats. AA
67  2014 Ginsenoside metabolite compound K promotes recovery of dextran sulfate sodium-induced colitis and inhibits inflammatory responses by suppressing NF-kappaB activation. BBR, DSS, MPO
68  2014 Ginsenoside metabolite compound K stimulates glucagon-like peptide-1 secretion in NCI-H716 cells via bile acid receptor activation. ---
69  2013 Bioconversion of ginsenosides in the american ginseng ( xi yang shen) extraction residue by fermentation with lingzhi ( ling zhi, ganoderma lucidum). ---
70  2013 Biotransformation of ginsenoside Rd in the ginseng extraction residue by fermentation with lingzhi (Ganoderma lucidum). ---
71  2013 Compound K induces apoptosis of bladder cancer T24 cells via reactive oxygen species-mediated p38 MAPK pathway. ROS
72  2013 Compound K, a final intestinal metabolite of ginsenosides, enhances insulin secretion in MIN6 pancreatic beta-cells by upregulation of GLUT2. GLUT2
73  2013 Compound K, an intestinal metabolite of ginsenosides, inhibits PDGF-BB-induced VSMC proliferation and migration through G1 arrest and attenuates neointimal hyperplasia after arterial injury. CDK, PCNA, VSMC
74  2013 Differential effects of ginsenoside metabolites on slowly activating delayed rectifier K(+) and KCNQ1 K(+) channel currents. KCNE1, PPT
75  2013 Inhibitory Effects of Ginsenoside Metabolites, Compound K and Protopanaxatriol, on GABAC Receptor-Mediated Ion Currents. GABAC, PD, PT
76  2013 Joint-protective effects of compound K, a major ginsenoside metabolite, in rheumatoid arthritis: in vitro evidence. FLS, MMPs, NFATc1, RA, RANKL, TRAP
77  2012 Absorption mechanism of ginsenoside compound K and its butyl and octyl ester prodrugs in Caco-2 cells. AP-BL, P-gp
78  2012 Effects of protopanaxatriol-ginsenoside metabolites on rat N-methyl-d-aspartic Acid receptor-mediated ion currents. NMDA, PPD, PPT
79  2012 Ginsenoside compound K, not Rb1, possesses potential chemopreventive activities in human colorectal cancer. ---
80  2012 Hypoglycemic effect of protopanaxadiol-type ginsenosides and compound K on Type 2 diabetes mice induced by high-fat diet combining with streptozotocin via suppression of hepatic gluconeogenesis. G6Pase, OGTT, PDG, PEPCK
81  2012 Identification and characterization of the Rhizobium sp. strain GIN611 glycoside oxidoreductase resulting in the deglycosylation of ginsenosides. ---
82  2012 Inhibition of P-glycoprotein leads to improved oral bioavailability of compound K, an anticancer metabolite of red ginseng extract produced by gut microflora. MDR1, P-gp
83  2011 Compound K increases type I procollagen level and decreases matrix metalloproteinase-1 activity and level in ultraviolet-A-irradiated fibroblasts. MMP, UV
84  2011 Compound K, a metabolite of ginsenosides, induces cardiac protection mediated nitric oxide via Akt/PI3K pathway. Akt, eNOS, PI3K
85  2011 Differential effects of ginsenoside metabolites on HERG k channel currents. hERG, Ideactivating-tail, PPD, PPT
86  2011 Effects of Minor Ginsenosides, Ginsenoside Metabolites, and Ginsenoside Epimers on the Growth of Caenorhabditis elegans. PPD, PPT
87  2011 Ginsenoside compound K attenuates metastatic growth of hepatocellular carcinoma, which is associated with the translocation of nuclear factor-kappaB p65 and reduction of matrix metalloproteinase-2/9. HCC
88  2011 Ginsenoside metabolite compound K differentially antagonizing tumor necrosis factor-alpha-induced monocyte-endothelial trafficking. HUVEC
89  2011 Inhibition of JAK1/STAT3 signaling mediates compound K-induced apoptosis in human multiple myeloma U266 cells. JAK1, PTP, STAT3
90  2011 Ultra-performance liquid chromatography and time-of-flight mass spectrometry analysis of ginsenoside metabolites in human plasma. AUC
91  2010 Compound K inhibits basic fibroblast growth factor-induced angiogenesis via regulation of p38 mitogen activated protein kinase and AKT in human umbilical vein endothelial cells. bFGF, HUVECs, MAPK, PEDF, VEGF
92  2010 Effect and mechanism of ginsenosides CK and Rg1 on stimulation of glucose uptake in 3T3-L1 adipocytes. AMPK, PI3K
93  2010 Intestinal metabolite compound K of ginseng saponin potently attenuates metastatic growth of hepatocellular carcinoma by augmenting apoptosis via a Bid-mediated mitochondrial pathway. ---
94  2009 Compound K induces apoptosis via CAMK-IV/AMPK pathways in HT-29 colon cancer cells. AMPK, CAMK-IV
95  2009 Compound K, intestinal metabolite of ginsenoside, attenuates hepatic lipid accumulation via AMPK activation in human hepatoma cells. ACC, AMPK, FAS, HMGR, LDLR, PPAR-alpha, SCD1, SREBP-1c
96  2009 Glucocorticoid receptor agonist compound K regulates Dectin-1-dependent inflammatory signaling through inhibition of reactive oxygen species. ERK, GR, IL, NADPH, ROS
97  2009 Studies on absorption, distribution and metabolism of ginseng in humans after oral administration. AUC, G-Rb1
98  2008 The ginsenoside metabolite compound K, a novel agonist of glucocorticoid receptor, induces tolerance to endotoxin-induced lethal shock. GR, GRE, LPS, MAPKs, TLR
99  2007 Anti-diabetic effects of compound K versus metformin versus compound K-metformin combination therapy in diabetic db/db mice. HOMA-IR
100  2007 Compound K enhances insulin secretion with beneficial metabolic effects in db/db mice. OGTT